Why Is TYRA BIOSCIENCES INC (TYRA) Stock Up Today?

TYRA stock rose 13.80% to $25.07 in intraday trading on Sept. 14, 2026, driven by the company’s announcement of a $400 million underwritten offering of common stock and pre-funded warrants. The offering is intended to fund the development of dabogratinib, a key therapeutic candidate in TYRA’s pipeline. The move follows recent regulatory filings and renewed analyst coverage, which have drawn investor attention to the company’s capital-raising efforts and strategic direction.

What Happened

Tyra Biosciences priced the $400 million offering, which includes 9.079 million shares of common stock at $22.03 per share and an equal number of pre-funded warrants. The offering is set to close on Sept. 15, 2026. The company also filed an automatic shelf registration for future securities offerings, signaling its intent to access capital markets as needed. Cantor Fitzgerald recently reiterated its stock rating, contributing to the heightened interest. The stock’s sharp rise coincided with broader market movements, as highlighted by several news outlets, though the primary catalyst was the capital-raising announcement.

What The Data Shows

The stock traded at $25.07, up from $23.66 over the prior eight sessions, which had seen a 5.8% decline. The recent price action coincided with a 52-week high on Sept. 14, marking the 27th such high of the year. Insider activity has been limited but positive, with one insider purchasing shares for $20,000 in the last 90 days. The stock’s beta of 0.73 suggests it has historically traded below the broader market’s volatility, though its recent intraday move defied that trend.

What To Watch

The offering is set to close on Sept. 15, 2026, and investors may monitor the company’s next steps in funding and advancing its dabogratinib programs. Coverage of the stock has increased in the past 36 hours, with six stories from five sources, indicating growing market interest.